Overview

• Anthem Biosciences shares debuted at Rs 723 apiece on both NSE and BSE, delivering a 27% premium over the IPO’s Rs 570 issue price.
• The Rs 3,395-crore book-built IPO was subscribed 63.86-times overall, driven by a 182.65-times subscription from qualified institutional buyers.
• Conducted solely as an offer-for-sale, the listing directed all proceeds to existing shareholders without raising fresh equity.
• Grey market premiums near Rs 177 ahead of listing implied a potential 31% upside for investors.
• Bengaluru-based Anthem operates as a technology-focused CRDMO with end-to-end drug development and manufacturing services, aligning with global pharma’s China+1 sourcing shift.